Completed PHASE1 INTERVENTIONAL 4-arm NCT02503085

Ibuprofen Suspension Bioequivalence Study

A Randomized, Single-dose, 4-way Crossover, Open-label, Pharmacokinetic (PK) Study Comparing a 2% (w/v) Suspension of Ibuprofen (400 mg/20 mL Nurofen for Children®) With a Swiss Reference 2% (w/v) Suspension of Ibuprofen (400 mg/20 mL Algifor Dolo Junior®) in the Fed and Fasted States

Sponsor: Reckitt Benckiser Healthcare (UK) Limited

Conditions Healthy Volunteer Study

Interventions Algifor Dolo Junior® Nurofen for Children®

Updated 6 times since 2017 Last updated: Apr 11, 2018 Started: Jun 2, 2015 Primary completion: Aug 25, 2015 Completion: Aug 25, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02503085, this PHASE1 trial focuses on Healthy Volunteer Study and remains completed. Sponsored by Reckitt Benckiser Healthcare (UK) Limited, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
May 2018 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — May 2018 [monthly]

Completed PHASE1

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Reckitt Benckiser Healthcare (UK) Limited

Data source: Reckitt Benckiser Healthcare (UK) Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hull, United Kingdom